$KROS insider trading
Over the last 12 months, Keros Therapeutics insiders reported 5 buys totaling $65K and 17 sales totaling $194.5M across SEC Form 4 filings. 45% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $65K 5 events
- Sold · 12m
- $194.5M 17 events
- Events · 12m
- 22 Form 4 filings, grouped
- Insiders · 12m
- 14 distinct reporters
- 10b5-1 share
- 45% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | Tanini AnnitaCorp. Controller & VP, Finance · O | ▼ Sale | 1,224 | $10.29 | $13K | -2.6% | — |
| Aug 18, 2026 | Lerner Lorena RaquelChief Scientific Officer · O | ▼ Sale | 3,568 | $10.29 | $37K | -11.5% | — |
| Aug 18, 2026 | Cho EstherChief Legal Officer · O | ▼ Sale | 4,485 | $10.29 | $46K | -11.1% | — |
| Aug 18, 2026 | Newton Charles W.D | ▼ Sale | 551 | $10.3 | $6K | -4.4% | plan |
| Aug 17, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 1,000 | $10.27 | $10K | +5.4% | plan |
| Jul 15, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 1,000 | $10.61 | $11K | +5.7% | plan |
| Jun 15, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 1,000 | $10.19 | $10K | +6% | plan |
| Jun 11, 2026 | Newton Charles W.D | ▼ Sale | 550 | $10.04 | $6K | -4.2% | plan |
| Jun 4, 2026 | Farzan NimaD | ▼ Sale | 2,625 | $10.73 | $28K | -21.2% | plan |
| Jun 4, 2026 | Knowles JuliusD | ▼ Sale | 2,625 | $10.73 | $28K | -19.3% | plan |
| Jun 4, 2026 | Seth AlpnaD | ▼ Sale | 2,625 | $10.72 | $28K | -21.2% | plan |
| Apr 15, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 1,000 | $11.7 | $12K | +13.4% | plan |
| Mar 9, 2026 | BIENAIME JEAN JACQUESD | ▲ Buy | 2,000 | $11.21 | $22K | +36.7% | plan |
| Feb 19, 2026 | Seehra JasbirCHIEF EXECUTIVE OFFICER · O·D | ▼ Sale | 7,015 | $16.17 | $113K | -1.8% | — |
| Feb 18, 2026 | Cho EstherSVP, General Counsel · O | ▼ Sale | 4,745 | $16.35 | $78K | -10.7% | — |
| Feb 18, 2026 | Lerner Lorena RaquelChief Science Officer · O | ▼ Sale | 3,873 | $16.35 | $63K | -11.1% | — |
| Feb 18, 2026 | Regnante KeithCHIEF FINANCIAL OFFICER · O | ▼ Sale | 4,739 | $16.35 | $77K | -10.8% | — |
| Nov 21, 2025 | Knowles JuliusD | ▽ Sale to issuer | 322,021 | $17.75 | $5.7M | -75.9% | late · 2 tranches · indirect |
| Nov 21, 2025 | ORBIMED ADVISORS LLCD | ▽ Sale to issuer | 214,522 | $17.75 | $3.8M | -82.6% | late · 2 tranches · indirect |
| Nov 21, 2025 | GORDON CARL LD | ▽ Sale to issuer | 214,522 | $17.75 | $3.8M | -82.6% | late · 2 tranches · indirect |
| Oct 15, 2025 | Pontifax Management 4 G.P. (2015) Ltd.10% | ▼ Sale | 4,787,331 | $17.75 | $85.0M | -100% | 4 tranches · indirect |
| Oct 15, 2025 | ADAR1 Capital Management, LLC10% | ▼ Sale | 5,389,264 | $17.75 | $95.7M | -100% | 3 tranches · indirect |
Every $KROS filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Keros Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $KROS feed.